The University of Rochester Patent applications |
Patent application number | Title | Published |
20160137778 | SHAPE MEMORY POLYMERS AND METHODS OF MAKING AND USE THEREOF - Described are shape memory polymers and methods of making shape memory polymers and actuators from the shape memory polymers. | 05-19-2016 |
20160106743 | TOPOISOMERASE II POISONS AND METHODS OF MAKING AND USING SAME - Disclosed herein are compositions of Formula I and an optional anticancer drug. Also disclosed herein are methods of treating or preventing cancer using the same. | 04-21-2016 |
20150289772 | Implantable Pressure Monitor - There is provided an implantable pressure monitor having a fluid sack in contact with a body part of a patient where the fluid sack is retained to the body part by a pressure monitor housing that may have various attachment means. The fluid sack is filled with a liquid such as silicone oil. The pressure monitor housing has an opening that provides access to a fistula with a fluid valve that terminates through the fluid sack. A fiber optic pressure sensor is in contact with the liquid in the fluid sack by way of the fistula and fluid valve. In some embodiments of the present invention, an electronics module is incorporated with the implantable pressure monitor to provide telemetry, power, and the like. | 10-15-2015 |
20150105401 | MLK INHIBITORS AND METHODS OF USE - Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases. | 04-16-2015 |
20110289605 | Animal Model for Osteoarthritis and Intervertebral Disc Disease - Provided herein is a transgenic animal whose genome comprises a first nucleic acid sequence encoding a fusion polypeptide, wherein the fusion polypeptide comprises a Cre recombinase and a mutated ligand binding domain of human estrogen receptor (CreER), wherein the first nucleic acid is operably linked to a chondrocyte-specific promoter and a second nucleic acid sequence encoding a β-catenin polypeptide, wherein the second nucleic acid sequence comprises one or more loxP sequences. Also provided is a method of modifying a transgenic animal comprising administering tamoxifen to the transgenic animal. Also provided are methods of screening for an agent that reduces or prevents Cre-Negative Control one or more symptoms of osteoarthritis or intervertebral disc disease in a subject. Methods for identifying a subject with or at risk of developing osteoarthritis or intervertebral disc disease are also provided, as well as methods of treating or preventing osteoarthritis or intervertebral disc disease in a subject. | 11-24-2011 |
20110268748 | NURR-1 Interacting Protein (NuIP) - Provided herein are methods of promoting the activity of Nurr1 in a cell comprising contacting the cell with NuIP or an analog or fragment thereof. Also provided are methods of treating or preventing a condition associated with reduced dopaminergic function in a subject, comprising administering to the subject NuIP or an analog or fragment thereof. Methods of inhibiting the activity of Nurr1 in a cell comprising contacting the cell with a NuIP inhibitor are provided. Methods of screening for agents that modulate the interaction of Nurr1 and NuIP are also provided. | 11-03-2011 |
20100119450 | SOLUBLE LOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN BINDS DIRECTLY TO ALZHEIMER'S AMYLOID-BETA PEPTIDE - A soluble derivative of low-density lipoprotein receptor related protein-1 (sLRP-1) binds directly to Alzheimer's amyloid-β peptide (Aβ). This binding may be used to detect Aβ or to separate Aβ from the rest of a subject's body. In Alzheimer's disease, it may be used to provide diagnostic results by detecting Aβ, treatment by removing Aβ, or both. | 05-13-2010 |